Snapshot from Sep 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Business public offering

PMV Pharma $50.8M Public Offering

Analysis based on 8 articles · First reported Aug 31, 2026 · Last updated Sep 01, 2026

Sentiment
10
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The offering is expected to provide PMV Pharma with approximately $50.8 million in gross proceeds, strengthening its balance sheet to fund ongoing research and development. The dilutive nature of the offering may pressure the stock price in the near term, but the capital infusion supports the company's clinical programs and reduces financing risk.

Biotechnology Pharmaceuticals

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company developing small molecule therapies targeting p53, announced on August 31, 2026 the pricing of an underwritten public offering. The offering consists of 22,055,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 19,900,000 shares, along with accompanying warrants to purchase 41,955,000 shares of common stock. The combined public offering price is $1.21 per share and accompanying warrant, and $1.20999 per pre-funded warrant and accompanying warrant. Gross proceeds are expected to be approximately $50.8 million before expenses. Toronto-Dominion Bank — TD Cowen is acting as sole book-running manager. The offering is expected to close on or about September 2, 2026, subject to customary conditions. The securities are offered under a shelf registration statement on Form S-3 filed with the United States — United States Securities and Exchange Commission. The company plans to use the proceeds for general corporate purposes, including advancing its pipeline of p53-targeted cancer therapies.

80 PMV Pharmaceuticals priced public offering
stock
PMV Pharma is the issuer of the offering, raising approximately $50.8 million to fund its operations and pipeline. The capital raise provides financial runway but dilutes existing shareholders.
Importance 100.0 Sentiment 10.0
subs
Toronto-Dominion Bank — TD Cowen acted as sole book-running manager for the offering, earning underwriting fees and enhancing its reputation in biotech capital markets.
Importance 20.0 Sentiment 5.0
govactor
The SEC is the regulatory body overseeing the offering through the shelf registration process, ensuring compliance with securities laws.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.